Navigation Links
New Ovarian Cancer Drug Trial Under Way
Date:9/7/2007

Phenoxodiol could help women resistant to other medicines

FRIDAY, Sept. 7 (HealthDay News) -- Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

In previous studies, phenoxodiol has shown some success in helping traditional chemotherapies continue to fight cancer cells.

The Phase III study of phenoxodiol will take place at 30 sites in the United States, 26 sites in Europe and at least four sites in Australia.

The goal of the Web site, www.OVATUREtrial.com, is to inform ovarian cancer patients about the Ovarian Tumor Response (OVATURE) trial, which is actively recruiting patients. Women suffering with ovarian cancer can learn about the study, the medication and locations for them to participate.

The trial is studying the safety and effectiveness of the drug phenoxodiol when combined with weekly doses of the chemotherapy drug carboplatin. Phenoxodiol is believed to help chemotherapy drugs kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy. Phenoxodiol has not yet been approved for use by the U.S. Food and Drug Administration.

Women who enter the trial will be assigned to one of two courses of treatment. The first will receive weekly carboplatin and phenoxodiol. Patients in the other course will receive carboplatin and a placebo weekly. Patients and their doctors will not know which course of treatment they have been given.

Receiving carboplatin weekly instead of every two or three weeks has been shown to provide tumor response in some patients with recurrent ovarian cancer. The study will expand understanding of the safety and effectiveness of both phenoxodiol and weekly carboplatin.

Phenoxodiol has been shown to reverse resistance to standard chemotherapies in lab animals. In a prior Phase II clinical trial, the drug showed some success in reversing tumor progression when it was tested in combination with cisplatin or paclitaxel.

Ovarian cancer occurs in one out of every 69 women and is the fifth leading cause of cancer death in women, according to the Ovarian Cancer National Alliance. It can be treated if diagnosed early, but most ovarian cancers are caught at later stages. When diagnosed in an advanced stage, women have a 30 percent chance of surviving five years.

More information

To learn more about ovarian cancer, visit the Ovarian Cancer National Alliance.



-- Madeline Vann



SOURCE: OVATURE, press release, Aug. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Progestin protects against ovarian cancer
3. Inherited gene important in ovarian cancer
4. Blood test may identify ovarian cancer
5. Exercise lowers Risk of Ovarian Cancer
6. Screening device for ovarian cancer
7. Ethnic discrepancy in ovarian cancer
8. Associated scan for detecting ovarian cancer spread
9. Gene Mutation Causes Ovarian Failure
10. Ovarian Cancer Screening Questioned
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... With the Grand Opening Event planned for February 3, ... sports teams and the general public. Built in five months by Centerpoint, the 60,000 ... into basketball or pickleball courts. The space is also suitable for indoor soccer and ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... manufacturer Prairie Seating. Prairie’s award-winning Reflection® brand of custom seating systems has a ... acquisition provides Permobil with a platform for innovation and growth in the custom ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: January 9, 2017 ... Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, author, ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... San Francisco ... iTero Element, the latest in 3-D scanning device which is capable of taking digital ... latest advances in dentistry, such as CAD CAM restorations , in terms of ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Oregon and PUNE, India ... to a new report published by Allied Market Research, ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the global ... by 2022, from $5,768 million in 2015, growing at ... chemical & gas sterilization segment dominated the market in ...
(Date:1/16/2017)... , January 16, 2017 According to a new report ... Analysis and Industry Forecast, 2014 - 2022," the global antioxidants market generated $2,923 ... a CAGR of 6.42% during the forecast period. In the natural antioxidants category, ... in 2015. Continue Reading ... ...
(Date:1/16/2017)... 2017   Linde Gas North America LLC  today ... and business of The Service Center LLC, a market leading ... healthcare providers in the Midwest and Southeast regions of the ... , The Service Center also has facilities in ... Carolina . Its primary services include: ...
Breaking Medicine Technology: